Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5647
Source ID: NCT01465152
Associated Drug: Metformin
Title: Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: metformin|DRUG: repaglinide
Outcome Measures: Primary: Change of % HbA1c (glycosylated haemoglobin) in blood | Secondary: Change of the mean body mass index calculated as weight in kilograms divided by the square of height in metres|Incidence of clinical and/or biochemistry hypoglycaemia episodes|Incidence of adverse events|Presence of laboratory abnormalities in routine blood analyses|Change of the blood pressure and/or heart rate|Treatment compliance
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 182
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2002-03-06
Completion Date: 2004-10-21
Results First Posted:
Last Update Posted: 2017-02-20
Locations: Novo Nordisk Investigational Site, Barcelona, 08020, Spain|Novo Nordisk Investigational Site, Benamargosa, 29718, Spain|Novo Nordisk Investigational Site, Burlada, 31600, Spain|Novo Nordisk Investigational Site, Camas, 41900, Spain|Novo Nordisk Investigational Site, Fuenlabrada, 28942, Spain|Novo Nordisk Investigational Site, Gijón, 33212, Spain|Novo Nordisk Investigational Site, Granada, 18012, Spain|Novo Nordisk Investigational Site, Lugo, 27004, Spain|Novo Nordisk Investigational Site, Madrid, 28021, Spain|Novo Nordisk Investigational Site, Madrid, 28030, Spain|Novo Nordisk Investigational Site, Madrid, 28035, Spain|Novo Nordisk Investigational Site, Portugalete, 48920, Spain|Novo Nordisk Investigational Site, San Adria del Besos, 08930, Spain|Novo Nordisk Investigational Site, Santander, 39009, Spain|Novo Nordisk Investigational Site, Santander, 39011, Spain|Novo Nordisk Investigational Site, Tegueste, 38280, Spain|Novo Nordisk Investigational Site, Valencia, 46021, Spain|Novo Nordisk Investigational Site, Zaragoza, 50007, Spain
URL: https://clinicaltrials.gov/show/NCT01465152